Citadel Advisors
SYRS

Citadel Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Citadel Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,700
Closed -$391 – 15925
2024
Q4 		$391 Sell
1,700
-35,200
-95% -$42.3K ﹤0.01% 14335
2024
Q3 		$79.3K Buy
36,900
+33,700
+1,053% +$121K ﹤0.01% 11422
2024
Q2 		$16.5K Buy
3,200
+2,700
+540% +$14.2K ﹤0.01% 12785
2024
Q1 		$2.67K Sell
500
-600
-55% -$4.15K ﹤0.01% 13984
2023
Q4 		$8.57K Buy
+1,100
New +$3.77K ﹤0.01% 13213
2022
Q1 		– Sell
-2,040
Closed -$67K – 14782
2021
Q4 		$67K Sell
2,040
-4,940
-71% -$200K ﹤0.01% 13074
2021
Q3 		$312K Sell
6,980
-3,050
-30% -$149K ﹤0.01% 10994
2021
Q2 		$547K Buy
10,030
+950
+10% +$56.2K ﹤0.01% 9873
2021
Q1 		$679K Buy
9,080
+1,340
+17% +$139K ﹤0.01% 9014
2020
Q4 		$840K Buy
+7,740
New +$706K ﹤0.01% 7159

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's SYRS Position: Q3 2024 in Review

Citadel Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 26,622 shares — an estimated $95.6K sold.

Citadel Advisors first reported a position in SYRS in Q3 2017 and held it in 13 quarters. The position peaked at $5.22M in Q1 2021. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • Citadel Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 26,622 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $95.6K.
  • Citadel Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 13 quarters.
  • Citadel Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $5.22M in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.